Abstract:
PURPOSE: A pharmaceutical composition containing dehydroglyasperin C is provided to suppress nerve cell injury and apoptosis and to improve cognitive function. CONSTITUTION: A pharmaceutical composition for treating cognitive function reduction contains dehydroglyasperin C of chemical formula 1 as an active ingredient. The cognitive function reduction is caused by stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington' disease, Pick disease, or Creutzfeldt-Jakob disease. A health functional food for reducing cognitive function reduction contains dehydroglyasperin C of chemical formula 1. The health functional food is a tablet, capsule, pill, or liquid.
Abstract:
PURPOSE: A pharmaceutical composition containing sulforaphane or sulforaphane precursors or derivatives is provided to effectively prevent or treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains 0.1-50 wt% of sulforaphane of chemical formulas 1-9 or sulforaphane precursors or derivatives as an active ingredient. The concentration of the sulforaphane, precursors, or derivatives is 10 uM-1mM. The pharmaceutical composition is used in a form of plasters, granules, lotions, liniments, lemonades, aromatic waters, powders, syrups, liquids and solutions, aerosols, extracts, elixirs, ointments, fluid extracts, emulsions, suspensions, decoctions, infusions, tablets, suppositories, injections, spirits, cataplasma, capsules, creams, pastes, pills, or soft or hard gelatin capsules.
Abstract:
PURPOSE: A composition containing dehydroglyasperin D(DHGA-D) for preventing or treating cutaneous disorders is provided to suppress MMP-1 expression and reduce p38 and JNK phosphorylation. CONSTITUTION: A composition for preventing or treating cutaneous disorders contains 10uM-1mM of dehydroglyasperin D(DHGA-D) as an active ingredient. The cutaneous disorders include skin aging, dermatitis, or skin cancer. The composition is a pharmaceutical composition. The formulation of the pharmaceutical composition includes plasters, granules, lotions, liniments, lemonades, aromatic waters, powders, syrups, ophthalmic ointments, liquids and solutions, aerosols, extracts, elixirs, ointments, fluid extracts, emulsions, suspensions, decoctions, infusions, pills, or soft or hard gelatin capsules.
Abstract:
본 발명은 카페인산 페네틸에스테르(Caffeic Acid Phenethyl Ester, CAPE)를 유효성분으로 함유하는 것을 특징으로 하는 비만 예방용 식품 조성물 또는 비만 치료용 제약 조성물에 관한 것으로, 지방 축적 억제 효과, 지방 전구세포가 지방 세포로 분화될 때 촉진되는 세포 주기 진행 억제 효과, 지방 세포로의 분화시 발현되는 중요한 전사인자들인 C/EBPβ, C/EBPα, PPARγ의 발현 저해 효과, 지방 세포로의 분화시 촉진인자인 사이클린(Cyclin) A의 발현 저해 효과를 발휘하는 카페인산 페네틸에스테르를 유효성분으로 함유함으로써 우수한 비만 예방 또는 치료효과를 발휘한다. 비만 예방, 비만 치료, 세포 주기 조절(Cell cycle arrest), 지방 분화 억제, 카페인산 페네틸에스테르(Caffeic Acid Phenethyl Ester, CAPE), C/EBPβ, C/EBPα, PPARγ, Cyclin A
Abstract:
PURPOSE: A method for rearrangement of genomic DNA is provided to change specific gene using zinc-finger nuclease. CONSTITUTION: A target-specific nuclease is used in deletion, duplication, inversion, or rearrangement of genomic DNA by two or more cleaving specific sites. The target-specific nuclease is a zinc finger nuclease. The zinc finger nuclease contains two or more zinc finger modules. The zinc finger nuclease recognizes different two sites.